Analyst Price Target is $43.00
▲ +79.47% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Avidity Biosciences in the last 3 months. The average price target is $43.00, with a high forecast of $50.00 and a low forecast of $36.00. The average price target represents a 79.47% upside from the last price of $23.96.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Avidity Biosciences.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.